Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: (650) 515-3185

Fax: (650) 351-0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

PleadNoContest Jul. 28 at 2:15 PM

$CTMX Look at that BOOMING volume!

1 · Reply

Korrok_Soy_Sauce Jul. 28 at 2:02 PM

$CTMX k

0 · Reply

Korrok_Soy_Sauce Jul. 28 at 10:23 AM

$CTMX

0 · Reply

alcat1973 Jul. 25 at 8:54 PM

$CTMX Steady she goes. Has been rock solid since last earnings. Yes, it's been somewhat boring, but boring is ok. Holding up like a champ.

2 · Reply

smolcapcat Jul. 25 at 2:40 PM

$CTMX its been so long since we've had a decent discount. this ticker barely reacts to anything going in the sector. I hope Aug 1st liberation day 2.0 tariffs or w/e tank it

0 · Reply

PleadNoContest Jul. 24 at 5:59 PM

$CTMX Brother went down!

0 · Reply

Turdsniffer Jul. 23 at 8:06 PM

$CTMX higher f$&king low! Let’s fu$@ing go! I still think we test 2.80 by Friday

0 · Reply

PleadNoContest Jul. 23 at 4:57 PM

$CTMX Ready to hit the extreme high point in 5, 4, 3 weeks. Til then this will never move up. Insiders and institutions are holding it down. Volume? Almost none. Just go on vacation for 3 weeks.

0 · Reply

AITechBot Jul. 23 at 2:22 AM

$DFLI My CISO position will soon join the 100% club! $CISO Cybersecurity on steroids through a subscription model where companies pay a premium for coverage! BRILLIANT!!!🤑🤑🚀🚀✅🤫🤫 $CTMX

1 · Reply

winners18 Jul. 22 at 11:13 PM

$CTMX https://finance.yahoo.com/news/bispecific-antibodies-market-set-surge-072000581.html

0 · Reply

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 2 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 2 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 2 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 2 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 2 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 2 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 3 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 3 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 5 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 5 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 5 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 5 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 7 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 8 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 9 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 9 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 11 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 11, 2024, 6:39 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Dec 21, 2023, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 2:32 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

Oct 31, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

Oct 18, 2023, 4:30 PM EDT - 1 year ago

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

Sep 5, 2023, 4:05 PM EDT - 2 years ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 10, 2023, 4:05 PM EDT - 2 years ago

CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

Aug 8, 2023, 10:57 PM EDT - 2 years ago

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

PleadNoContest Jul. 28 at 2:15 PM

$CTMX Look at that BOOMING volume!

1 · Reply

Korrok_Soy_Sauce Jul. 28 at 2:02 PM

$CTMX k

0 · Reply

Korrok_Soy_Sauce Jul. 28 at 10:23 AM

$CTMX

0 · Reply

alcat1973 Jul. 25 at 8:54 PM

$CTMX Steady she goes. Has been rock solid since last earnings. Yes, it's been somewhat boring, but boring is ok. Holding up like a champ.

2 · Reply

smolcapcat Jul. 25 at 2:40 PM

$CTMX its been so long since we've had a decent discount. this ticker barely reacts to anything going in the sector. I hope Aug 1st liberation day 2.0 tariffs or w/e tank it

0 · Reply

PleadNoContest Jul. 24 at 5:59 PM

$CTMX Brother went down!

0 · Reply

Turdsniffer Jul. 23 at 8:06 PM

$CTMX higher f$&king low! Let’s fu$@ing go! I still think we test 2.80 by Friday

0 · Reply

PleadNoContest Jul. 23 at 4:57 PM

$CTMX Ready to hit the extreme high point in 5, 4, 3 weeks. Til then this will never move up. Insiders and institutions are holding it down. Volume? Almost none. Just go on vacation for 3 weeks.

0 · Reply

AITechBot Jul. 23 at 2:22 AM

1 · Reply

winners18 Jul. 22 at 11:13 PM

$CTMX https://finance.yahoo.com/news/bispecific-antibodies-market-set-surge-072000581.html

0 · Reply

bryantboy99 Jul. 22 at 10:44 PM

$CTMX can we get a $ABVX type run in the future?

0 · Reply

SumDay1Day Jul. 22 at 8:02 PM

Last post before we all go honor Ozzy My watches for tomorrow $ITRG $IXHL $NCNA $CTMX And we will see what else $PAPL has in her. Goodluck tomorrow and comment below what you are watching along the week.

1 · Reply

SumDay1Day Jul. 22 at 7:45 PM

R.I.P Ozzy Really interrupted my $IXHL $CTMX and $CELU trades. Might call it a day to honor the Prince of Darkness.

0 · Reply

deerix Jul. 22 at 1:11 PM

$XAIR Stop doubting me for once. People like to bash, hate, and troll until I screenshot how much I am up since my first call. Do I win all my trades? No Do I win a lot of them, with an exceptional risk-to-reward, YES! I did 600%+ and 1400%+ on $OPEN and $VOR, respectively. That is just in a little more than ONE month. Not to talk about the 300%+ I did on $CTMX one month before that There goes work into the stocks I pick, and it shows in the results. I even mentioned it ➡️

0 · Reply

alcat1973 Jul. 21 at 7:46 PM

$CTMX Hey, CTMX management- A PR this week would be very helpful and supportive to all of your believers out here.

1 · Reply

PleadNoContest Jul. 21 at 7:31 PM

$CTMX Now you know to sell as it approaches $2.50. Earnings are not for at least 3 weeks.

0 · Reply

smolcapcat Jul. 21 at 5:40 PM

$CTMX too strong, don't like it, go back to 2.10s

1 · Reply

Turdsniffer Jul. 21 at 4:50 PM

$CTMX thought 2.80 was the next test, not 2.20

1 · Reply

smolcapcat Jul. 21 at 3:45 PM

$CTMX resilient ticker but need it to bleed more

0 · Reply

MicahbRr Jul. 21 at 3:32 AM

$CTMX “not quite my tempo”

0 · Reply

GenslerSVJ Jul. 20 at 11:23 PM

$CTMX Will consider long on next update for lead asset. Very promising data

0 · Reply

GenslerSVJ Jul. 20 at 11:04 PM

From 2024, $CTMX leading the pack now. Many of these dead

0 · Reply

Market Cap	193.49M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	4.98
Forward PE	N/A
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	1,332,800
Avg Vol	2,695,092
Day's Range	N/A - N/A
Shares Out	80.62M
Stochastic %K	41%
Beta	2.05
Analysts	Strong Sell
Price Target	$5.50